Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) Revenue (2020 - 2023)

Gain Therapeutics (GANX) has 4 years of Revenue data on record, last reported at $55180.0 in Q1 2023.

  • For Q1 2023, Revenue rose 22.61% year-over-year to $55180.0; the TTM value through Dec 2023 reached $55180.0, down 60.62%, while the annual FY2023 figure was $55180.0, 58.4% down from the prior year.
  • Revenue reached $55180.0 in Q1 2023 per GANX's latest filing, down from $95102.0 in the prior quarter.
  • Across five years, Revenue topped out at $95102.0 in Q2 2022 and bottomed at $5269.0 in Q1 2021.
  • Average Revenue over 4 years is $30354.5, with a median of $12142.0 recorded in 2021.
  • The widest YoY moves for Revenue: up 1097.8% in 2021, down 21.04% in 2021.
  • A 4-year view of Revenue shows it stood at $9138.0 in 2020, then skyrocketed by 32.87% to $12142.0 in 2021, then surged by 683.25% to $95102.0 in 2022, then tumbled by 41.98% to $55180.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Revenue were $55180.0 in Q1 2023, $95102.0 in Q2 2022, and $45006.0 in Q1 2022.